EXOZYMES INC. Financing Cash Flow
EXOZYMES INC. (EXOZ) reported Financing Cash Flow of $5.84 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- EXOZYMES INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $5.85M.
- EXOZYMES INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$12.74K.
- EXOZYMES INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$10.55K, a 100.07% decline year-over-year.
- EXOZYMES INC. net cash provided by (used in) financing activities for the quarter ending 2025-03-31 was -$43.25K.
- EXOZYMES INC. net cash provided by (used in) financing activities for fiscal 2025 was -$27.71K, a 100.15% decline from fiscal 2024.
- EXOZYMES INC. net cash provided by (used in) financing activities for fiscal 2024 was $18.52M, a 1751.76% increase from fiscal 2023.
- EXOZYMES INC. net cash provided by (used in) financing activities for fiscal 2023 was $1.00M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $5.84M 10-Q · filed 2026-08-13 | $5.83M derived: sum of 3 quarters · filed 2026-08-13 | |
| 2026-03-31 | -$12.74K 10-Q · filed 2026-05-14 | -$23.29K derived: sum of 2 quarters · filed 2026-05-14 | ||
| 2025-12-31 | -$10.55K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$27.71K 10-K · filed 2026-03-30 | ||
| 2025-09-30 | -$17.16K 10-Q · filed 2025-11-13 | |||
| 2025-03-31 | -$43.25K 10-Q · filed 2026-05-14 | $15.36M derived: sum of 2 quarters · filed 2026-05-14 | $15.95M derived: sum of 3 quarters · filed 2026-05-14 | $18.57M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $15.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $15.99M derived: sum of 2 quarters · filed 2026-03-30 | $18.61M derived: sum of 3 quarters · filed 2026-03-30 | $18.52M 10-K · filed 2026-03-30 |
| 2024-09-30 | $586.36K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $3.21M derived: sum of 2 quarters · filed 2025-11-13 | $3.11M 10-Q · filed 2025-11-13 | $3.60M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $2.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $2.53M 10-Q · filed 2025-08-12 | $3.01M derived: sum of 3 quarters · filed 2025-08-12 | |
| 2024-03-31 | -$91.51K 10-Q · filed 2025-05-12 | $393.49K derived: sum of 2 quarters · filed 2025-05-12 | ||
| 2023-12-31 | $485.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.00M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $515.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |